Document is current
Any future updates will be listed below
-
Authors
Newell, Abigail https://orcid.org/0000-0003-1790-7277
Fortune, Erica E.
Andac-Jones, Elif
Gonzalo, Maria B.
Szamreta, Elizabeth A.
-
Funding
Funding for this research was provided by:
Merck (#V7730 (PROVINCE - Real-time patient-reported outcome monitoring in ovarian cancer))
- License Information
-
More Information
Article History
Received: 23 June 2025
Accepted: 10 March 2026
First Online: 23 March 2026
Declarations
:
: Data collected for this study was part of a protocol approved by WCG IRB (WCG Protocol #20224718). Prior to participating in the survey, participants reviewed and completed an electronic consent form that was approved by WCG IRB.
: Not applicable.
: Abigail Newell reports institutional research funding from Merck, AstraZeneca, Pfizer, Bristol Myers Squibb, and Gilead. Erica E. Fortune reports institutional research funding from Astellas, Merck, AstraZeneca, Bristol Myers Squibb, and Gilead. Maria Gonzalo has no competing interests to report. Elif Andac-Jones reports institutional funding from AstraZeneca, Beigene, Genentech, Gilead, Jazz, Lilly, Merck, Novartis, Pfizer, Roche, and Seagen. Elizabeth Szamreta reports employment by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stock holdings with Merck & Co., Inc., Rahway, NJ, USA.
